Key Ingredients: Simple, straightforward, and designed around your comfort
BPC-157 has never undergone human clinical trials for any indication no phase 1 safety data, no pharmacokinetic studies, no efficacy trials
Although precision therapy for individual patients remains limited, combination therapy has the potential to enhance treatment efficacy while potentially reducing reliance on highly toxic chemotherapy (24)
Noteworthily, the concomitant use and mutual counteraction of cytoprotective agents and non-steroidal anti-inflammatory drugs (NSAIDs) has been a common proof of the cytoprotective concept [32,33,34,35,36,37,38,39,40,41,42]
This points to the possibility that the peptide could influence extracellular matrix maintenance, hydration, and skin barrier strength in laboratory settings